Entact

Entact Bio is a preclinical-stage biotechnology company developing a new class of drugs that enhance the function of beneficial proteins. Founded by a team deeply rooted in deubiquitinase (DUB) biochemistry, chemical biology, disease biology, and small molecule drug development, Entact has designed its proprietary Encompass™ platform to create Enhanced Targeting Chimeric (ENTAC)™ drugs. ENTACs leverage the ability of DUBs to modulate proteins. By harnessing this natural cellular mechanism to enhance protein function, Entact is expanding the range of treatable diseases.